This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma | MicrobiomeTrials
← Back to trials NCT05967182
A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma Recruiting PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2024-01-16Est. Completion: 2027-07-31
Enrollment target: 24 participantsLocations M D Anderson Cancer Center, Houston, Texas, United States Other microbiome trials you might be interested in Intrahepatic Cholangiocarcinoma (Icc)
This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety o…
Guangzhou, China Est. completion Jan 2030
Colorectal Neoplasms Neoplasms Intrahepatic Cholangiocarcinoma Adrenocortical Carcinoma Metastasis, Neoplasm
Background:
Cancers that begin in the colon, adrenal glands, or bile ducts may spread to the liver. These liver tumors …
Bethesda, United States
Est. completion Dec 31, 2029
Colorectal Neoplasms Gastric Neoplasms Cholangiocarcinoma Bile Duct Cancer Pancreas Cancer
Background:
\- Recent advances in cancer research have led to new therapies to treat the disease. It is important to co…
Bethesda, United States Est. completion Jun 30, 2035